explore -WSS

explore

author：focus 2025-08-12 11:29:01 - browse：74516

Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global head of its Alzheimer’s disease unit, will retire at the end of the month. The surprise announcement comes just days after Eisai won final approval in the U.S. for its Alzheimer’s drug Leqembi.

Cheung will be replaced in his capacity as head of the Alzheimer’s unit by his brother-in-law Keisuke Naito, 34, who is currently chief ecosystem officer and chief strategy officer. He is also the son of Eisai CEO Haruo Naito.

Tatsuyuki Yasuno, current chief financial officer, will replace Cheung as head of Eisai’s U.S. unit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： CZI to create biohub to build anti

WSS

UCSF medical school apologizes for unethical prisoner experiments

White House calls on federal agencies to crack down on AI abuses

J&J lung cancer data amount to new salvo against AstraZeneca

Readout LOUD podcast: Live from the 2023 STAT Summit

Why a market frenzy over new weight loss drugs defies logic

ADCs take center stage as promising cancer treatments

explore

explore

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Will General Catalyst be the first of many hospital takeovers?

What does generative AI mean for health care? We asked experts

Medicare solvency divides Republicans at the presidential debate

The high cost of giving birth even with insurance

UCSF medical school apologizes for unethical prisoner experiments

Continuity nursing helped my family in our darkest PICU moments

Free speech concerns arise in wake of journal editor Eisen's firing

Walensky prepares to leave CDC — and Congress — behind

Health tech investors get more selective as pandemic boom fades

entertainment

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

The Sacklers, horror, and ‘The Fall of the House of Usher’

Just how powerful is the placebo effect?

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

The new shift in health care is toward less care

Health tech investors get more selective as pandemic boom fades

focus

focus

explore

hotspot